SCHEMBL4933945

SCHEMBL4933945

CC(=O)c1ccc(-c2c(C(=O)O)[nH]c3ccc(NS(=O)(=O)c4ccc(C(C)(C)C)cc4)cc23)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.59
MEN1 O00255 3/20 0.59
KMT2A Q03164 3/20 0.59
ALDH1A1 P00352 2/20 0.59
BRD4 O60885 1/20 0.52
PTPN5 P54829 1/20 0.49
SERPINE1 P05121 1/20 0.48
HDAC3 O15379 2/20 0.47
HDAC11 Q96DB2 2/20 0.47
HDAC8 Q9BY41 2/20 0.47
HDAC6 Q9UBN7 2/20 0.47
TP53 P04637 1/20 0.45
CA12 O43570 1/20 0.44
CA9 Q16790 1/20 0.44
UQCRB P14927 2/20 0.43
HPGD P15428 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
CYP1A2 P05177 1/20 0.42
POLB P06746 1/20 0.42
CYP2D6 P10635 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3947323 0.90 BRD4 (0.54) MAPTMEN1KMT2AALDH1A1BRD4
SCHEMBL4930867 0.90 UQCRB (0.56) MAPTMEN1KMT2AALDH1A1BRD4
SCHEMBL3945167 0.90 BRD4 (0.61) MAPTMEN1KMT2AALDH1A1BRD4
SCHEMBL4927787 0.90 BRD4 (0.52) MAPTMEN1KMT2AALDH1A1BRD4
SCHEMBL3946651 0.90 BRD4 (0.53) MAPTMEN1KMT2AALDH1A1BRD4
SCHEMBL4933597 0.90 GPR35 (0.53) MAPTMEN1KMT2AALDH1A1BRD4
Dimethylamine SCHEMBL4931369 0.89 BRD4 (0.59) MAPTMEN1KMT2AALDH1A1BRD4
SCHEMBL3950737 0.88 MEN1 (0.58) MAPTMEN1KMT2AALDH1A1BRD4
SCHEMBL4931366 0.88 BRD4 (0.52) MAPTMEN1KMT2AALDH1A1BRD4
SCHEMBL3949114 0.88 BRD4 (0.53) MAPTMEN1KMT2AALDH1A1BRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060074084-A1 Inhibitors of soluble adenylate cyclase BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2006-04-06 US claimed
US-20080004268-A1 INHIBITORS OF SOLUBLE ADENYLATE CYCLASE NGUYEN DUY 2008-01-03 US disclosed
US-20060074084-A1 Inhibitors of soluble adenylate cyclase BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2006-04-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004268-A1 INHIBITORS OF SOLUBLE ADENYLATE CYCLASE ADCY1, ADCY2, ADCY5 MAPT 4671/4885MEN1 712/4885KMT2A 4518/4885
US-20060074084-A1 Inhibitors of soluble adenylate cyclase ADCY1, ADCY2, ADCY5 MAPT 4671/4885MEN1 712/4885KMT2A 4518/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.